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Abstract
The majority of children with Down syndrome (DS) develop Alzheimer’s disease (AD) at an early age. Although long-chain n-3 fatty acids
(FA) are protective of neurodegeneration, little is known about the FA status in DS. In the present study, we aimed to investigate whether
children with DS presented altered plasma and erythrocyte membrane phospholipids (PL) FA composition, when compared with their non-
affected siblings. Venous blood samples were analysed for plasma and erythrocyte membrane FA composition by TLC followed by GC
techniques. Lipid molecular species were determined by electrospray ionisation/tandem MS (ESI-MS/MS). FA analysis measured by stan-
dard GC showed an increased concentration of MUFA and a decreased concentration of plasmalogens in major PL fractions, but there were
no differences in the concentrations of arachidonic acid or DHA. However, as identified by ESI-MS/MS, children with DS had increased
levels of the following erythrocyte PL molecular species: 16 : 0–16 : 0, 16 : 0–18 : 1 and 16 : 0–18 : 2n-6, with reduced levels of
16 : 0–20 : 4n-6 species. Children with DS presented significantly higher levels of MUFA in both plasma and erythrocyte membrane, as
well as higher levels of saturated and monounsaturated molecular species. Of interest was the almost double proportion of
16 : 0–18 : 2n-6 and nearly half the proportion of 16 : 0–20 : 4n-6 of choline phosphoacylglycerol species in children with DS compared
with their non-affected siblings. These significant differences were only revealed by ESI-MS/MS and were not observed in the GC analysis.
Further investigations are needed to explore molecular mechanisms and to test the association between the pathophysiology of DS and the
risk of AD.
Key words: Down syndrome: Phospholipids: MS: Alzheimer’s disease
Down syndrome (DS) is a major genetic disorder caused by
trisomy of chromosome 21, leading to recognisable physical
and facial features and several chronic disorders. The preva-
lence of this disorder is approximately one in 660 live
births(1), and it increases with maternal age(2). DS is the
leading cause of genetically defined intellectual disability
and congenital birth defects.
In the UK, one to two children with DS are born every day,
and they present a much higher risk of developing leukaemia,
diabetes, heart disease, premature ageing and dementia,
and Alzheimer’s disease (AD)-like pathology at the age of
30–40 years(3,4) when compared with non-affected children.
Early onset of AD has been causally related to the overexpres-
sion of b-amyloid precursor protein, which is one of the triple
genes in DS(5,6).
Another gene located on chromosome 21 is the superoxide
dismutase (SOD-1) gene. Its overexpression leads to a dramatic
increase in SOD-1 enzyme activity(7,8). This consequence is
thought to disturb the natural antioxidant enzyme balance in
individuals with DS, inducing oxidative stress(9,10). Increased
levels of oxidative stress have been detected in children with
DS(11), and concomitantly higher activities of other antioxidant
enzymes, including glutathione peroxidase (GPx) and catalase,
have also been reported to be increased(12,13).
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The brain is particularly vulnerable to lipid peroxidation(14)
due to its high content of oxidisable PUFA, especially DHA
(22 : 6n-3), which is a major plasma membrane fatty acid
(FA) component, essential for brain development, signal trans-
duction and synaptic function(15). Increased lipid peroxidation
has been suggested as a mechanism leading to AD(16), and
even more specifically, chronic losses of DHA are thought
to contribute to AD(17,18). Furthermore, low levels of EPA
(20 : 5n-3), one of the precursors of DHA, are considered as
a predictor of dementia risk(19). Moreover, neuroprotectin
D1, a derivative of DHA, has been reported to preserve
neuronal systems from oxidative stress and potentially
protect from neurodegeneration as in AD(20), but only very
little information is available about the status of PUFA in
people with DS.
Cell membrane lipid composition is directly influenced by
environmental variables, particularly diet, and abnormalities
of membrane lipid composition and metabolism have been
implicated in type 2 diabetes(21), obesity(22) and AD(23). It is
not known yet whether the cell membrane FA composition
is altered in children with DS, or whether any alteration in
their cell membrane lipids might be related to the increased
risk of developing diabetes, obesity, early mental decline
and AD. Nutrition has been suggested as an interventional
strategy aiming to prevent or reduce glycoxidation damage
that appears to play a role in cognitive deterioration and the
early onset of dementia in people with DS(24); however, no
data are available about the influence of PUFA supplements
on the well-being of people with DS.
The aim of the present study was to investigate whether the
extra copy of chromosome 21 has an influence on the FA
composition of phospholipids (PL) in the erythrocyte
membrane of children with DS, when compared with their
non-affected siblings. TLC, GC and electrospray ionisation/
tandem MS (ESI-MS/MS) were employed to study the possible
changes in the PUFA profile and intact PL molecular species.
Our data provide evidence that the FA profile of PL in
erythrocyte membrane and plasma is significantly modified
in children with DS. While PUFA and plasmalogen species
are markedly reduced, the content of SFA and MUFA is
dramatically increased.
Subjects and methods
Subjects
A total of twenty-five families with children with DS and their
non-affected siblings volunteered for the present study con-
ducted at the Holloway Mother and Baby Clinic (HMBC), at
London Metropolitan University, through advertisement
posted on the Down Syndrome Research Foundation website.
We aimed to compare children with DS with their unaffected
siblings to help control for family backgrounds, dietary
patterns and social status, which could interfere with the
outcomes of the study. The present study was conducted
according to the guidelines laid down in the Declaration of
Helsinki, and all procedures were approved by the Ethics
Committee of London Metropolitan University, and endorsed
by the Down Syndrome Research Foundation. Written
informed consent was obtained from the parents, and verbal
consent was obtained from the children, witnessed and
formally recorded.
Diet analysis
A 7 d food diary was obtained from all the participants before
the interview, sent by post to the State Registered Dietitian,
and analysed. The records were analysed by the dietitian
using the software/database FOODBASE version 3.1, which
is based on ‘McCance and Widdowson’s The Composition
of Foods’ and its ten accompanying supplements(25), and
enhanced FA data produced by the Institute of Brain
Chemistry and Human Nutrition. The food diary and nutrition
software has been validated previously(26). The diet provided
thorough data on nutrient intake and, particularly, each
member of the n-6 and n-3 FA classes.
Subsequent to the food diary, the families were invited by
the dietitians (N. B. and M. M. N.) for an interview at the
HMBC. Dietetic advice was given to the families based on
the diet analysis, and particular attention was paid to diet
habits, details that might have been under- or over-reported
in the diaries, and the use of nutrient supplements. Children
who were taking vitamins or food supplements, even sporadi-
cally, were excluded from the present study, as well as
children who were taking food supplements up to 2 months
before the appointment. A number of children were consum-
ing fish oil or other nutritional supplements; consequently,
both the child with DS and the non-affected sibling were
excluded. Only the results for nine families are reported in
the present study.
Blood collection
A non-fasting 3 ml venous blood sample was collected in
EDTA tubes at the HMBC by a locum nurse after the interview.
The blood sample was immediately taken to the Institute of
Brain Chemistry and Human Nutrition laboratory, centrifuged,
and plasma, buffy coat and erythrocyte fractions were
obtained. Erythrocytes were washed three times with Dulbecco’s
PBS (Sigma). All aliquots were flushed with oxygen-free N2
and frozen at 2808C until analysis.
Lipid extraction and fatty acid analysis
Total lipids were extracted from erythrocytes and plasma by
the method of Folch et al.(27), and FA analysis was performed
according to standard procedures as reported previously(28).
Briefly, erythrocyte samples (1 ml) were homogenised in
45 ml chloroform–methanol (2:1, v/v) containing 0·01 % buty-
lated hydroxytoluene under oxygen-free N2. Ethanolamine,
choline, serine phosphoacylglycerols (PtdEtn, ChoGpl
and PtdSer) and sphingomyelin (CerPCho) were separated
with chloroform–methanol–methylamine (65:35:15, by vol.)
on 20 £ 20 cm2 silica gel TLC plates (VWR International)
at room temperature. Plasma samples were extracted and
separated in the same manner. The plasma neutral lipids
A. A. Bueno et al.2
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cholesterol esters and TAG were scraped from the plasma TLC
plates, washed with petroleum ether–diethyl ether (50:50,
v/v) and separated with petroleum ether–diethyl ether–
formic acid–methanol (85:15:2·5:1, by vol.) on TLC plates at
room temperature. The lipid bands were detected by spraying
with 2,7-dichlorofluorescein (0·01 %, w/v) in methanol,
visualised under UV light and compared with authentic
standards (Sigma). FA methyl esters were obtained by heating
the PL fractions scraped from the TLC plates with 15 % acetyl
chloride in dry methanol in a sealed tube at 708C for 3 h under
oxygen-free N2. The reaction was stopped by the addition of
5 % NaCl solution at room temperature, and FA methyl ester
were extracted by washing three times with petroleum
ether containing 0·01 % butylated hydroxytoluene. FA methyl
ester were separated by GC (HRGC MEGA 2 series; Fisons
Instruments) fitted with a capillary column (BPX70; Thames
Restek). Peak areas were quantified (EZChrom Chromato-
graphy Data System; Scientific Software, Inc.), values are
expressed as the percentage of total FA, and the calculation
of area percentage was assumed to be equivalent to weight
percentage.
Enzyme activity determination
Erythrocyte SOD (U/ml; where one unit is defined as the
amount of enzyme needed to exhibit 50 % dismutation of
the superoxide radical), GPx (nmol/min per ml) and catalase
(nmol/min per ml) were analysed by commercially available
ELISA kits (Cayman Chemicals), according to the instructions
of the manufacturer.
Electrospray ionisation-MS/MS
ESI-MS/MS measurements were performed on a Q-TOF Micro
hybrid quadrupole time-of-flight mass spectrometer (Waters
Corporation), as described previously(29). Briefly, erythrocyte
lipids were extracted with a mixture of hexane–isopropanol
(3:2, v/v) containing 0·01 % butylated hydroxytoluene. The
samples were washed with chloroform–methanol–water
(2:1:1, by vol.). After low-speed centrifugation, the organic
layer was isolated, evaporated to dryness and lipids
partitioned again in the chloroform layer of a chloroform–
methanol–water solution (8:4:3, by vol.). The chloroform
layer containing the crude lipid extracts was evaporated to
dryness and dissolved in methanol–chloroform (2:1, v/v) to
a concentration ,5 pmol/ml and infused directly into the
ESI chamber at a flow rate of 5–8ml/min. Typically, a
1–2 min period of signal averaging was employed for each
spectrum. The capillary was operated at 22·5 kV in the
positive-ion mode. Desolvation temperature was maintained
at 1808C. MS data were processed with MassLynx 4.0 software
(Waters Corporation) to produce peak list files. The identities
of all indicated molecular species were confirmed by ESI-MS/
MS. To acquire suitable product-ion spectra, collision energies
were varied between 25 and 35 eV. 13C isotope effects were
corrected by determining the individual type II 13C isotope
correction factor, as described previously(30). For positive-ion
analyses and identification of positively charged PL species,
aliquots of lipid extracts were treated with CHCl3–CH3OH–
50 mM-NH4Cl (2:1:1, by vol.) in order to minimise the contri-
butions of metal ions allowing the formation of [M þ H]þ
adducts, thus simplifying ESI-MS/MS spectra. Subsequently,
LiOH (final concentration 2 mM) was added to the samples
to allow the formation of [M þ Li]þ adducts and facilitate
informative fragmentation by MS/MS. These samples were
not used for quantification as alkaline treatment might
induce some PL hydrolysis.
Statistical analysis
Results are presented as means and standard deviations. For
the analysis of PL molecular species, we tested for differences
between children with DS and their non-affected siblings by
the Mann–Whitney U test. For the other analysis, Student’s
t test was used. Differences were considered statistically
significant at P,0·05. Details about sample sizes are given
in the individual table and figure legends.
Results
A total of twenty-five families with children with DS and their
non-affected siblings volunteered for the present study; how-
ever, not all children were able to participate fully in the study.
The analysis of a 7 d food diary for each child revealed signifi-
cant differences in their n-9, n-6 and n-3 FA intake due to
PUFA-containing food supplements in various concentrations,
from various suppliers. Hence, children who were taking any
fish oils, vitamins or other supplements, even sporadically,
were excluded from the present study, as well as those who
had taken supplements, up to 2 months before the appoint-
ment and blood sampling. Thus, only children from nine
families were included in the present study. The average age
for healthy siblings was 9·2 (SD 4·4) years, and for children
with DS was 5·9 (SD 3·7) years (statistically similar). The
study contained four boys and seven girls in the healthy sib-
ling group, and five boys and four girls in the DS group
(Table 1). The average intakes of energy and nutrients, specifi-
cally n-3, n-6 and n-9 FA, were similar between children with
DS and their unaffected siblings (data not shown).
Lipid analysis
Blood samples were collected and lipid extracts were
prepared from erythrocytes and plasma. Following separation
of the various PL fractions by TLC, GC analysis revealed the
Table 1. Age and sex of children with Down syndrome (DS) and their
healthy siblings (HS)
(Mean values with standard deviations, n 11 for HS and n 9 for DS)
HS DS
Mean SD Mean SD
Age (years) 9·2 4·4 5·9 3·7
Boys (n) 4 5
Girls (n) 7 4
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changes in the FA profile of PL fractions in erythrocyte
membrane, as well as changes in PL and neutral lipid fractions
in plasma. The major PL classes, i.e. the aminophosphoacyl-
glycerols (PtdEtn and PtdSer) which are rich in PUFA, and
the rather SFA-rich PL (ChoGpl and CerPCho) of erythrocyte
membrane were analysed, as well as plasma ChoGpl, TAG
and CE.
In the erythrocyte membrane PtdEtn of children with DS,
the amount of the major SFA 16 : 0 was increased by 14 %,
causing the total amount of SFA to be elevated when
compared with the samples of healthy siblings (Table 2).
The amount of the major MUFA 18 : 1n-9 was increased by
7·3 %, and that of a minor MUFA, 18 : 1n-7, was elevated by
16 %. In contrast to the other PL classes, PtdEtn is rather rich
in a particular group of phosphoacylglycerols measurable
by GC analysis as fatty aldehyde dimethylacetals (DMA).
DMA species are the cleavage products of 1-alkenyl 2-acyl
phosphoacylglycerol species, also known as plasmalogens.
Plasmalogens consist of an aldehyde in the sn-1 position,
giving rise to a single vinyl ether double bond and
a long-chain hydrocarbon containing a carboxyl group
esterified to the sn-2 position of the glycerol moiety posses-
sing between two to six double bonds. The amount of 18 : 0
DMA, reflecting the major plasmalogen PtdEtn species in
erythrocyte membrane, was reduced by more than 20 % in
children with DS.
Of the n-6 PUFA families, the amounts of two n-6 FA
(18 : 2n-6 and 22 : 4n-6) were found to be altered in the eryth-
rocyte membrane PtdEtn of children with DS. The amount
of dietary essential FA linoleic acid (18 : 2n-6) was increased
by 15 %, while its metabolic elongation and desaturation
product 22 : 4n-6 was decreased by 18 %. Consequently,
the ratio 18 : 2n-6/20 : 4n-6 was increased and the ratio
22 : 4n-6/22 : 5n-6 was decreased. There were no statistically
significant changes in the distribution of n-3 PUFA (Table 2)
in this PL fraction.
Analysis of the FA profile in erythrocyte membrane PtdSer,
the second PUFA-rich PL class, revealed no significant differ-
ences in the amounts of SFA, MUFA or n-3 and n-6 PUFA.
However, the amount of 18 : 0 DMA, a minor species in
PtdSer since plasmalogens are not as prominent in PtdSer as
in PtdEtn, was reduced on average by 68 % in children with
DS compared with their healthy siblings.
ChoGpl represents the major PL class in erythrocyte mem-
brane as well as in plasma. In the erythrocyte membrane
ChoGpl of children with DS, the amount of the major SFA
16 : 0 was increased from 33 to 36 % of the total ChoGpl FA,
while that of 18 : 0 was decreased from 12 to 11 %, resulting
in an elevated amount of SFA when compared with the
samples of unaffected siblings (Table 3). A similar trend
could be found in plasma ChoGpl, although the numbers
were less significant (Table 3). While the major MUFA
(18 : 1n-9) in erythrocyte membrane and plasma ChoGpl
remained unchanged, its isomer 18 : 1n-7 was increased from
1·5 to 1·8 % (a 20 % increase), and from 1·3 to 1·7 % (a 31 %
increase), in erythrocyte membrane and plasma ChoGpl,
respectively. In addition, another n-7 FA, palmitoleic acid
(16 : 1n-7), was significantly elevated in plasma ChoGpl.
Table 2. Fatty acid (FA) composition of erythrocyte ethanolamine (PtdEtn) and serine phosphoacylglycerols
(PtdSer) in children with Down syndrome (DS) when compared with their healthy siblings (HS)
(Mean values and standard deviations of total FA (%), n 11 for HS and n 9 for DS)
PtdEtn PtdSer
HS DS HS DS
Mean SD Mean SD Mean SD Mean SD
16 : 0 12·85 0·87 14·69*** 0·75 5·73 1·79 5·28 1·77
18 : 0 5·68 0·52 5·84 0·60 39·53 2·64 40·79 1·95
SSFA 18·91 1·12 21·07*** 1·28 46·19 2·97 46·92 1·78
16 : 1n-7 0·19 0·04 0·20 0·10 0·27 0·55 0·12 0·07
18 : 1n-9 14·76 1·02 15·84* 1·31 7·88 2·30 6·41 1·08
18 : 1n-7 0·87 0·12 1·01* 0·10 0·66 0·16 0·77 0·23
SMUFA 16·25 1·10 17·55* 1·47 9·56 3·15 7·94 1·38
Sn-7 1·05 0·15 1·21* 0·15 0·93 0·59 0·89 0·26
18 : 0/18 : 1 0·37 0·05 0·35 0·04 4·98 1·40 5·92 1·64
16 : 0 DMA 4·79 0·56 4·26 0·76 0·18 0·11 0·14 0·11
18 : 0 DMA 9·30 0·84 7·33*** 0·78 0·25 0·09 0·17* 0·06
SDMA 15·57 1·41 13·02*** 1·60 0·57 0·33 0·35 0·16
18 : 2n-6 5·38 0·73 6·19 1·04 4·13 1·25 3·94 1·23
20 : 4n-6 22·20 1·58 20·97 1·90 23·19 4·10 22·38 3·87
22 : 4n-6 5·83 1·04 4·80* 0·72 2·30 0·52 2·55 0·49
Sn-6 PUFA 35·92 2·35 34·46 2·66 33·24 4·65 32·68 2·99
18 : 2n-6/20 : 4n-6 0·24 0·03 0·30* 0·06 0·19 0·07 0·18 0·08
22 : 4n-6/22 : 5n-6 7·23 0·82 5·89** 0·78 2·41 0·41 2·46 0·77
20 : 5n-3 1·59 0·77 1·45 0·58 0·58 0·28 0·49 0·16
22 : 6n-3 6·35 1·32 6·64 2·27 5·99 2·37 7·23 2·44
Sn-3 PUFA 12·26 2·25 12·78 2·62 9·47 2·95 11·68 2·58
DMA, fatty aldehyde dimethylacetals.
Mean value was significantly different from that of the HS group: *P,0·05, **P,0·01, ***P,0·001.
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Plasmalogen species are less abundant in ChoGpl when
compared with PtdEtn. However, the amounts of 16 : 0 DMA
and 18 : 0 DMA were significantly reduced in the erythrocyte
membrane of children with DS, causing an approximately
24 % decrease in total DMA. Changes in plasma ChoGpl
plasmalogens were not statistically significant.
The amounts of total n-6 FA were reduced in the erythrocyte
membrane ChoGpl of children with DS, mainly due to a 13 %
reduction in the amount of 20 : 4n-6. The amount of 20 : 5n-3
in the erythrocyte membrane and plasma ChoGpl of children
with DS was statistically similar to that found for their healthy
siblings; however, it showed a very strong tendency towards
reduction (P¼0·060 for erythrocytes and P¼0·067 for
plasma; Table 3).
The fourth PL fraction analysed in erythrocyte membrane
samples was CerPCho (Table 4). Overall, a tendency of the
increase in palmitic acid (16 : 0) values in the erythrocytes of
children with DS was observed (P¼0·067), but no significant
differences in the total amounts of SFA were found. The total
amount of MUFA was significantly increased, but no change in
any individual MUFA reached statistical significance. The ratio
18 : 0/MUFA decreased, and this result is consistent in nearly
all the fractions studied. The total amount of DMA tended to
be lower in the erythrocyte membrane CerPCho of children
with DS, but there was no increase in the amount of individual
DMA FA, and this result was repetitive in nearly all the fractions
studied. There were no statistically significant differences in the
amount of n-6 or n-3 PUFA (Table 4).
CE represent a major lipid fraction in plasma. GC analysis
revealed only minor changes in cholesterol esters SFA. As in
erythrocyte membrane and plasma ChoGpl, the amount of
18 : 0 was decreased in children with DS. The amount of
18 : 1n-7 was increased by 20 % in plasma cholesterol samples
of children with DS, but the values did not reach statistical
significance as in other fractions. No differences were found
for DMA or n-6 and n-3 PUFA. The amount of 20 : 5n-3 in
children with DS was not statistically different from that
found in their healthy siblings, but similarly to erythrocyte
and plasma ChoGpl data, it showed a strong tendency towards
reduction (P¼0·064; Table 4). No differences were found in
the FA composition of plasma TAG (data not shown).
Antioxidant enzymes
Enzyme activities of erythrocyte SOD, GPx and catalase were
determined. Erythrocyte SOD activity (U/ml) was found to be
increased by 25 % in the blood samples of children with DS
(P¼0·02; Fig. 1). GPx activity (nmol/min per ml) was
increased by 40 %. No differences were found for catalase
activities (data not shown).
Phospholipid molecular species analysis
PL molecular species in erythrocyte membrane were analysed
by MS (ESI/quadrupole time-of-flight) analysis. This technique
allows the resolution of intact PL in their native form directly
from crude lipid extracts without prior chromatographic
separation or derivatisation. Identification of all signals was
carried out by the product-ion tandem MS/MS method based
on characteristic fragmentation spectra for all peaks. Fig. 2(a)
Table 3. Fatty acid (FA) composition of erythrocyte and plasma choline glycerophospholipids in children
with Down syndrome (DS) when compared with their healthy siblings (HS)
(Mean values and standard deviations of total FA (%), n 11 for HS and n 9 for DS)
Erythrocyte Plasma
HS DS HS DS
Mean SD Mean SD Mean SD Mean SD
16 : 0 32·88 1·10 35·56*** 2·12 27·66 2·47 28·73 1·43
18 : 0 11·62 0·75 10·65* 1·14 13·87 1·06 12·69* 1·11
SSFA 45·12 1·04 46·94* 1·92 42·34 2·30 42·19 1·70
16 : 1n-7 0·49 0·16 0·48 0·17 0·65 0·12 0·93* 0·44
18 : 1n-9 16·10 0·97 16·85 1·43 11·34 1·72 12·75 3·27
18 : 1n-7 1·52 0·27 1·76* 0·16 1·34 0·25 1·66** 0·16
SMUFA 18·45 1·09 19·37 1·59 13·62 1·66 15·60 3·71
Sn-7 2·02 0·39 2·24 0·21 1·99 0·30 2·59** 0·47
18 : 0/18 : 1 0·66 0·07 0·58* 0·09 1·11 0·16 0·92* 0·23
16 : 0 DMA 0·62 0·09 0·51* 0·11 0·47 0·12 0·43 0·13
18 : 0 DMA 0·36 0·12 0·23* 0·07 0·11 0·05 0·10 0·05
SDMA 1·06 0·16 0·80** 0·18 0·64 0·18 0·58 0·19
18 : 2n-6 21·30 1·64 19·91 2·21 24·84 2·27 23·24 3·07
20 : 4n-6 6·49 0·77 5·65* 0·73 8·20 1·27 8·00 1·20
22 : 4n-6 0·34 0·08 0·29 0·06 0·25 0·06 0·30 0·08
Sn-6 PUFA 31·22 1·83 28·84** 1·74 37·24 2·22 35·57 2·79
18 : 2n-6/20 : 4n-6 3·33 0·47 3·61 0·82 3·13 0·75 3·00 0·77
22 : 4n-6/22 : 5n-6 1·17 0·94 0·73 0·22 0·69 0·17 0·89* 0·19
20 : 5n-3 0·81 0·37 0·54 0·18 1·23 0·57 0·81 0·34
22 : 6n-3 1·87 0·69 1·81 0·74 3·08 1·27 3·20 1·23
Sn-3 PUFA 3·48 1·03 3·22 0·83 5·44 1·77 5·35 1·46
DMA, fatty aldehyde dimethylacetals.
Mean value was significantly different from that of the HS group: *P,0·05, **P,0·01, ***P,0·001.
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shows a section of the positive-ion ESI-MS/MS spectrum of a
crude lipid extract of erythrocyte membrane from children
with DS. The major ChoGpl molecular species and the peak
assignment are shown in Fig. 2(a).
Palmitic acid (16 : 0) is one of the major SFA in various erythro-
cyte membrane PL (5–35% of total FA) and plasma ChoGpl and
CerPCho (28 and 22% of total FA, respectively) (Tables 2–4).
In the erythrocyte membrane ChoGpl of children with DS,
significant changes in the distribution among 16 : 0-containing
molecular species were found. ChoGpl species containing
shorter-chain and less unsaturated FA in the sn-2 position
(i.e. 16 : 0, 18 : 1 and18 : 2)weremore thandoubled (total increase
from 16 to 40% of all choline phosphoacylglycerol species),
while molecular species containing arachidonic acid (20 : 4n-6)
were significantly reduced. A relevant reduction was observed
in species containing DHA (22 : 6n-3), but it did not reach
statistical significance. The last two species (16 : 0, 20 : 4n-6
and 16 : 0, 22 : 5n-3) combined corresponded to 21 % of all
species in healthy siblings, but only 15 % in children with
DS (Fig. 2(b)).
Discussion
A child with DS is at a higher risk of diabetes, obesity, CVD,
dementia and early onset of AD. Although lipids are con-
sidered to play a role in the aetiology of all these disorders,
little is known as to whether or not there is a disturbance in
membrane lipids in DS. The double expression of SOD in
DS is thought to be a risk factor by promoting oxidative
stress conditions. The brain is especially rich in highly
unsaturated FA(31), which are susceptible to peroxidation(14).
Therefore, the aim of the present study was to assess the
status of membrane FA in children with DS compared with
their unaffected siblings. There were no differences in age
or sex among the children included in the study, and dietary
analysis revealed that the average intakes of energy and nutri-
ents were similar between siblings. Particular attention was
paid to fat intake, and it was found to be statistically similar.
Chromosome 21 contains several genes that have been
implicated in neurodegenerative mechanisms. These include
Cu/ZnSOD (SOD-1), E26 transformation-specific sequence
(Ets-2) transcription factors, DS critical region 1 (DSCR1)
stress-inducible factor, and the amyloid precursor protein
(APP) genes. The accumulation of Ab plaques is progressive
across the lifespan in DS(32). SOD-1 activity is found elevated
Table 4. Fatty acid (FA) composition of erythrocyte sphingomyelin (CerPCho) and plasma cholesterol
esters (CE) in children with Down syndrome (DS) when compared with their healthy siblings (HS)
(Mean values and standard deviations of total FA (%), n 11 for HS and n 9 for DS)
CerPCho Plasma CE
HS DS HS DS
Mean SD Mean SD Mean SD Mean SD
16 : 0 21·95 3·83 24·74 2·23 10·36 0·92 11·18 1·12
18 : 0 14·10 3·92 12·31 2·30 0·94 0·14 0·76* 0·18
SSFA 63·66 4·68 63·72 3·93 12·18 1·13 12·78 1·52
16 : 1n-7 0·15 0·13 0·11 0·06 2·55 0·85 2·33 0·98
18 : 1n-9 2·48 0·76 2·71 0·79 18·90 1·90 19·73 3·01
18 : 1n-7 0·28 0·07 0·32 0·09 0·96 0·24 1·15 0·19
SMUFA 19·63 3·34 22·33* 1·49 22·59 2·13 23·37 3·70
Sn-7 0·43 0·15 0·42 0·10 3·51 1·00 3·49 1·06
18 : 0/18 : 1 5·20 0·88 4·27* 1·08 0·05 0·01 0·04* 0·01
18 : 2n-6 2·17 0·80 2·18 0·53 53·90 3·05 53·00 4·98
20 : 4n-6 5·10 2·45 3·61 1·36 6·22 1·03 6·27 0·94
22 : 4n-6 1·09 0·70 0·79 0·41 0·03 0·02 0·03 0·02
Sn-6 PUFA 9·65 4·21 7·71 2·48 62·27 2·90 61·18 5·03
18 : 2n-6/20 : 4n-6 0·50 0·20 0·65 0·16 8·95 1·95 8·65 1·60
22 : 4n-6/22 : 5n-6 1·80 0·29 1·61 0·62 0·11 0·10 0·16 0·12
20 : 5n-3 0·19 0·10 0·18 0·15 1·15 0·65 0·71 0·22
22 : 6n-3 4·26 1·96 3·73 2·02 0·55 0·24 0·56 0·27
Sn-3 PUFA 5·95 2·74 5·21 2·23 2·36 0·90 1·97 0·50
Mean value was significantly different from that of the HS group: *P,0·05, **P,0·01, ***P,0·001.
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
SOD (U/ml)
* *
GPx (nmol/min per ml)
E
n
zy
m
e 
ac
ti
vi
ty
Fig. 1. Activities of erythrocyte superoxide dismutase (SOD: Down syndrome
(DS, ), n 8; healthy siblings (HS), n 7) and glutathione peroxidase (GPx:
DS, n 9; control ( ), n 7) in children with DS when compared with their HS.
Values are means, with their standard errors represented by vertical bars.
* Mean value was significantly different from that of the HS group (P,0·05).
One unit of SOD is defined as the amount of enzyme needed to exhibit 50 %
dismutation of the superoxide radical.
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in DS, which also occurs in conditions of oxidative stress, and
is associated with a compensatory increase in GPx activity(33).
Enhanced free radical generation and anti-oxidative imbalance
have been suggested to contribute to accelerated ageing and
the prevalence of the neuropathology of AD observed in
these individuals. In particular, erythrocyte GPx has been
found to significantly correlate with deficits in memory func-
tion among adults with DS(34).
The present results demonstrate that already in young
children, antioxidant enzyme activities of erythrocyte SOD
and GPx were significantly elevated. Reynolds(35) found that
antioxidant supplementation did not improve the develop-
ment of children with DS. Interestingly, a study assessing
total serum antioxidant activity levels, but in contrast to
previous reports, has found no significant difference between
control individuals and those with DS(36). However, increased
serum concentrations of lipid peroxidation products, i.e.
malondialdehyde, have been detected in blood samples
from individuals with DS(7), suggesting that enhanced
oxidative stress conditions might affect membrane lipid
composition and, in particular, the PUFA profile of PL.
Detailed analysis performed by using a combination of TLC
and GC techniques revealed significant changes in the FA pro-
file of PL fractions in erythrocyte membrane, as well as PL and
neutral lipid fractions in plasma. The first specific finding was
that shorter-chain (sixteen or eighteen carbons) and less unsa-
turated (none, one and two double bonds) FA (i.e. 16 : 0, 18 : 0,
18 : 1 and 18 : 2n-6) were increased in most lipid fractions ana-
lysed, while longer-chain (twenty and twenty-two carbons)
and highly unsaturated (four and five double bonds) FA
(i.e. 20 : 4n-6 and 22 : 4n-6) were reduced. The amount of
20 : 5n-3 was not significantly reduced, but presented a
strong tendency towards a reduction in erythrocyte membrane
ChoGpl (P¼0·060), plasma ChoGpl (P¼0·067) and plasma
cholesterol esters (P¼0·064). These perturbations might be a
consequence of increased oxidative stress conditions in
which highly unsaturated FA are oxidised and destroyed,
and shorter-chain and less unsaturated dietary precursor FA
are compensated for the loss in erythrocyte membrane or
plasma lipids.
To corroborate the aforementioned suggestion, more
evidence was found based on the changes in the erythrocyte
plasmalogen content of children with DS. Plasmalogens
consist of an aldehyde in the sn-1 position, giving rise to a
single vinyl ether double bond and a long-chain hydrocarbon
containing a carboxyl group esterified to the sn-2 position of
the glycerol moiety possessing anywhere between two and
six double bonds. It is the interplay between these two side
chains that creates a powerful antioxidant system that resides
in the hydrophobic domain to scavenge free radicals. Thus,
plasmalogens have been proposed as natural antioxidants
following oxidative stress insults based on their ability to
scavenge reactive oxygen species, such as peroxyl radicals
and singlet oxygen, as well as to chelate potentially harmful
metal ions(37–39). Furthermore, oxidation of the vinyl ether
bond has been suggested to prevent the oxidation of adjacent
PUFA, thus protecting PUFA from the consequences of free
radical attacks and the resulting epoxide, being a relatively
stable molecule(40,41). In the present study, erythrocyte
membrane plasmalogen species detected mainly as 18 : 0
DMA were significantly reduced in the erythrocytes of children
with DS, suggesting that chronic oxidative stress conditions
may have targeted and destroyed these phosphoacyl-
glycerols as a first line of defence. However, an increase in
plasmalogen oxidation products can be harmful and may as
well pose a problem in itself. Plasmalogen epoxides and
a-hydroxyaldehydes (powerful nucleophilic reagents that
can attack other biomolecules) are known to accumulate in
all chronic diseases such as atherosclerosis and myocardial
infarction, upon ageing as well as in AD and other neuro-
pathological conditions(42). Plasmalogen deficiency has been
described in other neurological disorders such as Zellweger
syndrome(43) and cerebral adrenoleukodystrophy(44).
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Fig. 2. Changes in choline phosphoacylglycerol (PC) molecular species in
the erythrocyte membrane lipids of children with Down syndrome (DS, )
when compared with their healthy siblings (HS). (a) Section of a represen-
tative positive-ion electrospray ionisation-MS/MS spectrum of erythrocyte
membrane PC from a healthy sibling . The spectrum shows [M þ H]þ
adducts only (see the ‘Subjects and methods’ section for details). (b) Pal-
mitic acid (16 : 0)-containing PC species are expressed as the percentage
of total erythrocyte membrane PC species. Values are means (HS, n 5;
DS, n 5), with standard deviations represented by vertical bars. * Mean
value was significantly different from that of the HS group (P,0·05). m/z,
mass:charge ratio; FA, fatty acid.
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In addition to changes in the major FA profile, significant
changes were detected for a minor FA that was found in
all the fractions analysed. cis-Vaccenic acid (18 : 1n-7,
11-octadecenoic acid and asclepic acid) is an n-7 isomer of
oleic acid (18 : 1n-9) and was elevated in the blood PL
fractions of children with DS. While oleic acid is the major
MUFA found in all cells and tissues, cis-vaccenic acid
comprises only about 1 % of all FA in the blood. However,
incorporation of cis-vaccenic acid into the erythrocyte
membrane has been shown to enhance the rate of adenylate
cyclase activation through the P-receptors. Adenylate cyclase
catalyses the conversion of ATP to 30,50-cyclic AMP, an
important second-messenger molecule involved in signal
transduction(45). The present results show a small, but highly
significant (P,0·005) increase in cis-vaccenic acid in
the blood samples of children with DS, possibly implicating
a potential disturbance of 30,50-cyclic AMP-related signalling
cascades.
While cis-vaccenic acid is a minor FA in erythrocyte
membrane, it is a major component of cardiolipin, a PL
found exclusively in bacterial and mitochondrial membranes.
It amounts up to 20 % of the PL of the mitochondrial mem-
brane, and its biological function in this organelle is clearly
crucial(46). It is located mainly in the inner mitochondrial
membrane, where it interacts with a large number of
mitochondrial proteins. This interaction affects the functional
activation of certain enzymes, especially those involved in
oxidative phosphorylation. Cardiolipin is an important
cofactor for cholesterol translocation from the outer to the
inner mitochondrial membrane, which plays a specific role
in the import of proteins into the mitochondria. It binds in a
highly specific way to DNA in chromatin, and appears to
have a functional role in the regulation of gene expression.
As opposed to other PL, in cardiolipin, cis-vaccenic acid, not
oleic acid, is the main octadecenoic acid present(47).
In the present study, we analysed blood samples only and
did not collect any data about possible changes in cis-vaccenic
acid in mitochondrial membranes. However, our data advo-
cate the importance to study the contents of cis-vaccenic
acid in other tissues. The erythrocyte membrane is a plasma
membrane with a similar composition to vascular endothelial
cells, which have the highest plasma membrane:cytosol
volume ratio. An abnormality in erythrocyte membrane is
likely to reflect vascular abnormality(48).
The lipid composition of cell membranes is directly
influenced by environmental variables, particularly diet, as
well as endogenous metabolic abnormalities (e.g. oxidative
stress). It is likely that the changes found in the erythrocyte
membrane of children with DS will also be found in the
lipid profile of other tissues. Hence, the changes in cis-
vaccenic acid found in the blood samples of children with
DS may reflect a similar increase in cis-vaccenic acid in
mitochondrial membranes, which may have an effect on cellu-
lar energy metabolism, particularly in tissues with high energy
consumption such as brain tissue.
In the present study, we used the ESI-MS/MS technique to
study the molecular distribution of individual FA in their
native form as intact PL, particularly because GC data revealed
that ChoGpl of children with DS showed a highly significant
increase in the amount of 16 : 0. We identified the pairing
profile at the sn-1 and sn-2 positions within the intact PL
molecules, a property that may underlie their mutual
interaction with membrane proteins. ESI-MS/MS is an
ionisation technique used for the mass spectrometric analysis
of polar compounds that was initially developed by Fenn
et al.(49). The utility of selective ESI ionisation is based on
the differential propensity of each lipid class to acquire
either positive or negative charges under the source high
voltage, thus lipid classes can be separated through their
endogenous electric potential. Each class of lipids can be
resolved in the ionisation source (intra-source separation),
and individual molecular species can be further identified by
MS and/or tandem MS (quadrupole time-of-flight).
Our data reveal profound changes in the distribution of FA
among the 16 : 0-containing molecular species. ChoGpl
species containing shorter-chain (eighteen carbons) and less
unsaturated (one and two double bonds) FA were almost
doubled, while molecular species containing long-chain
PUFA were reduced in children with DS. Of note is the
contrast between children with DS and their healthy siblings
in terms of the 16 : 0, 20 : 4n-6 species of choline phosphoacyl-
glycerols. In the unaffected siblings, the 16 : 0, 20 : 4n-6 species
was greater than the same linoleic acid precursor species
(16 : 0, 18 : 2n-6). However, in children with DS, the opposite
was the case: 18 : 2n-6 . 20 : 4n-6.
These changes are much more specific than the overall
increase in the amount of 16 : 0 ChoGpl detected by GC anal-
ysis and, of course, not noticeable in the GC data. The study
of molecular species provides additional information about
the conventional GC analysis on the percentage of FA, as it
is a description of lipids as they occur in the cell membrane.
As cell membrane PL are in intimate and functional contact
with executive proteins, this method is likely to be more
biologically representative of tissue status and so potentially
useful diagnostically. Variations in the molecular species
profile may cause modification in the interaction between PL
and the proteins anchored in them, possibly influencing
cell–cell interactions and cell signalling cascades.
The specific difference observed in linoleic/arachidonic
acid molecular species suggests a metabolic defect in the
conversion of linoleic to arachidonic acid, and/or specific
functional defects in the incorporation of these FA into
membrane PL. It is plausible that alteration of a specific
membrane PL is bringing about a different protein profile.
Conclusion
Lipid analysis of PL in plasma and erythrocyte membrane
revealed significant changes in the FA profile of children
with DS when compared with their healthy siblings, which
are not related to the differences in their diet intake. Moreover,
lipid abnormalities in erythrocyte membrane cannot be con-
sidered as an isolated phenomenon, but are likely to reflect
abnormal changes in the lipid profile of other cells and tissues
as well. Thus, establishing variations in the PL profile of other
organs is of utmost interest. Increased levels of SFA coinciding
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with decreased amounts of PUFA denote drastic changes in
the membrane lipid profile and may cause alterations in
membrane physical properties and function. In addition,
membrane PL PUFA serve as a molecular cache for NEFA,
i.e. arachidonic acid and DHA and their metabolites (e.g. PG
and neuroprotectins), which are key players in signalling
pathways regulating cell metabolism and stress response.
Taken together, alterations in membrane lipids found in the
present study may help to explain the increased risk of
developing CVD, metabolic and neurodegenerative diseases
in children and adults with DS.
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